Soleno Therapeutics, Inc. (SLNO) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A indicate a positive outlook with strong financial health, reduced expenses, and strategic expansion plans in the U.S. and EU. Despite some uncertainties and management's reluctance to provide specific metrics, the company's proactive market strategies and significant capital raise suggest optimism. The market cap suggests moderate volatility, aligning with a positive sentiment rating of 2% to 8%.
Key Financial Performance
Total Net Revenue $66 million, more than doubled from $32.7 million in the second quarter of 2025. The increase is attributed to strong launch momentum and growing awareness of VYKAT XR.
Net Income $26 million for the third quarter, compared to a net loss of $76.6 million in the same period of 2024. The profitability is due to increased revenue and effective cost management.
Cash from Operating Activities $43.5 million generated during the three months ended September 30, 2025. This reflects strong operational performance and revenue growth.
Cash, Cash Equivalents, and Marketable Securities $556.1 million at the end of the third quarter, including $230 million raised through an underwritten offering of common stock in July.
Cost of Goods Sold $1.1 million for the third quarter. A portion of the cost of goods sold included inventory at zero cost due to pre-approval manufacturing expenses.
Research and Development Expense $8.4 million for the third quarter, compared to $30.1 million in the same period of 2024. The decrease is due to reduced noncash stock-based compensation and fluctuating clinical program expenditures.
Selling, General, and Administrative Expense $33.8 million for the third quarter, compared to $49.2 million in the same period of 2024. The decrease is due to reduced noncash stock-based compensation, despite increased personnel and program investments.
Total Other Income Net $3.9 million for the three months ended September 30, 2025, compared to $3.6 million in the same period of 2024. The increase is attributed to higher interest income.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VYKAT XR launch success: VYKAT XR, the first FDA-approved treatment for hyperphagia in PWS patients aged 4 and older, achieved significant adoption with 764 active patients by the end of Q3. The product demonstrated efficacy and safety in clinical trials and real-world use, with adverse events being manageable. Discontinuation rates were below expectations, and the company is actively educating stakeholders to support adoption.
European market expansion: The company is pursuing regulatory approval for DCCR (marketed as VYKAT XR in the U.S.) in the EU. The EMA has validated the marketing authorization application, and the company is addressing questions from regulators. The EU market represents a significant opportunity with an estimated 9,500 PWS patients in key countries.
Revenue growth and profitability: Net revenue more than doubled from Q2 to $66 million in Q3, with a net income of $26 million. The company generated $43.5 million in cash from operations and has a strong cash position of $556.1 million, ensuring sufficient capital for U.S. launch and EU regulatory efforts.
Payer coverage and access: Achieved coverage for approximately 132 million lives, including policies from top 3 national PBMs and 40 state Medicaid programs. This broad access supports the product's adoption and addresses perceived barriers to prescribing.
Stakeholder engagement and education: The company is investing in educating healthcare providers, caregivers, and patients through initiatives like the PACE team, live community events, and physician-to-physician programs. These efforts aim to establish VYKAT XR as the standard of care for PWS-related hyperphagia.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Approval in the EU: The company is facing regulatory hurdles in obtaining approval for DCCR (marketed as VYKAT XR in the U.S.) in the EU. The process involves addressing day 120 questions from the EMA, which are similar to those discussed with the U.S. FDA. Delays or failure in obtaining approval could limit market expansion and revenue growth.
Adverse Events and Discontinuation Rates: The therapy VYKAT XR has reported adverse events such as hypertrichosis, edema, hyperglycemia, and rash. Although most are self-limiting, some require dose adjustments or treatment interruptions. The discontinuation rate due to adverse events has increased to 8%, with a total discontinuation rate of 10%, which could impact patient retention and long-term revenue.
Short Seller Report Impact: A short seller report released in mid-August disrupted the launch trajectory, leading to a lower number of patient start forms and increased discontinuations for non-serious adverse events. This has necessitated additional resources for education and outreach to rebuild trust and adoption.
Supply Chain and Cost of Goods Sold: The company is transitioning from 0-cost inventory to at-cost inventory for VYKAT XR. This will increase the cost of goods sold as a percentage of revenue, potentially impacting profit margins.
Market Penetration Challenges: Many prescribers and academic centers are still in the process of setting up designated PWS clinics, which could delay broader adoption of VYKAT XR. Additionally, perceived barriers such as lack of coverage or lengthy reimbursement paths may hinder prescriber adoption.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Regulatory Approval in Europe: Soleno is actively pursuing regulatory approval for DCCR (marketed as VYKAT XR in the U.S.) in the European Union. The company has submitted a marketing authorization application to the EMA, received day 120 questions, and is preparing responses. Approval in the EU would expand the addressable market significantly, with an estimated 9,500 people living with PWS in key European countries.
Market Expansion Plans: The company is prioritizing gaining approval in the EU and other geographies to expand its market reach. Diagnostic rates in Europe are high, and patient care is often concentrated around centers of excellence, similar to the U.S. market.
Future Revenue Growth: Soleno anticipates continued revenue growth driven by increasing adoption of VYKAT XR, expansion of prescriber base, and broadening payer coverage. The company is investing in stakeholder education and access resources to support this growth.
Operational Investments: The company plans to continue investing in personnel, educational initiatives, and programs to support the commercial launch of VYKAT XR and its expansion into new markets.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you comment on the restart rate with regard to the discontinuations you're seeing?
A:It is early, and there is a handful of people who have restarted. Anecdotally, others are planning to restart. No meaningful numbers are available yet.
Q:How many patients on active drug are still waiting for insurance clearance versus patient start forms?
A:All 764 patients have claims being reimbursed. The fill rate is around 30 days, with about 1 month in backlog of start forms.
Q:What is the impact of discontinuations and lower patient start forms due to the short report during the quarter?
A:There was a decrease in August and September, likely due to the short report and summer. October trends are similar to September. Efforts are being made to reach out to affected patients.
Q:Can you elaborate on the average dose across all patients currently on the drug?
A:The average dosing is still evolving. Most patients are aged 4-26, with progress in younger adults aged 27-45. Average weight is slightly heavier than in clinical trials.
Q:What percent of existing prescribers' PWS patients are currently on VYKAT?
A:About 10% of the TAM (1,000 start forms) is covered. There is room to grow, especially with KOL accounts. Prescribers are adding new patients during regular visits.
Q:What is the profile of adverse events leading to discontinuations?
A:Adverse events are on-label, such as low levels of peripheral edema or hyperglycemia. Most are nonserious, and patients often benefit if they stay on therapy.
Q:What type of patients or physicians need additional outreach and communication?
A:Community prescribers with 1-2 PWS patients need more education on the disease state and integrating VYKAT XR into their practice. Programs with national PWS experts are in place.
Q:What are the early learnings on efficacy and its impact on discontinuation rates?
A:Anecdotes show significant benefits, such as reduced food obsession and improved behavior. Patient webinars are helping to share positive experiences, which may reduce discontinuation rates.
Q:Is the time to securing reimbursement improving?
A:The target turnaround time is 30 days, which remains consistent. Variability exists depending on the channel.
Q:How is the disruption over the summer manifesting in the numbers?
A:There was a slowdown in start forms and anecdotal discontinuations due to the short report and summer. No specific metrics on missed refills are available.
Q:What are the long-term effects observed in patients on VYKAT?
A:Long-term data shows improvements in hyperphagia and quality of life, such as patients achieving personal milestones like running triathlons or graduating high school.
Q:Do you need additional efforts to find new patients?
A:Efforts are ongoing, including machine learning to optimize targeting. Claims data identifies approximately 12,000 PWS patients, with a TAM of 10,000.
Q:What proportion of patients reach or maintain their on-label dose?
A:Most patients reach their target dose, with a small minority undergoing dose reductions. Discontinuations typically occur within the first 3 months.
Q:When might you provide annualized revenue guidance?
A:It is too early to provide guidance. Maturation of the business is needed before considering this.
Q:How do you view Rhythm's expansion into PWS with setmelanotide?
A:The drug could be potentially synergistic due to different mechanisms. However, efficacy data is needed to determine its competitive or complementary role.
Q:Review of Unclear Management Responses
A:Management avoided providing specific metrics on the restart rate, the exact lag time between start forms and coverage, and the quantification of the impact of the short report on start forms and discontinuations. They also did not provide details on the 120-day questions from the EU or commit to a timeline for annualized revenue guidance.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
PWS VYKAT
VYKAT XR
XR experience
XR success
access
addition
approval commercialization
basis
cause
colleague
commitment
cost good
cost inventory
death
discontinuation rate
dose
education
embolism
event
expectation
fatality
form launch
form prescribers
heart failure
indicator start
individual VYKAT
inventory cost
journey
monitoring
mortality
number life
payer seriousness
potential
prescribers number
profitability income
reminder VYKAT
resource
state Medicaid
th
webcast
SLNO Transcript
Soleno Therapeutics, Inc. (SLNO) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call summary lacks substantial information on financial performance, product updates, market strategy, and shareholder returns. No explicit or implied risks were mentioned, and the Q&A section did not provide additional insights. Given the limited data, the stock price is likely to remain stable, hence a neutral prediction.
Soleno Therapeutics, Inc. (SLNO) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call summary and Q&A indicate a positive outlook with strong financial health, reduced expenses, and strategic expansion plans in the U.S. and EU. Despite some uncertainties and management's reluctance to provide specific metrics, the company's proactive market strategies and significant capital raise suggest optimism. The market cap suggests moderate volatility, aligning with a positive sentiment rating of 2% to 8%.
Soleno Therapeutics, Inc. (SLNO) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Neutral9-5
Soleno Therapeutics, Inc. (SLNO) Presents At Cantor Global Healthcare Conference 2025 Transcript
Neutral9-4
SLNO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
